


CP. Cure InSight

Cure Parkinson's Autumn/Winter 2025 Newsletter



BREAKING NEWS

Could a new trial platform change the future for people living with Parkinson's?

THE LATEST

Combination therapies: increasing the odds of finding disease-modifying therapies for Parkinson's.

Stepping out to mark 20 years of Cure Parkinson's - read more about our anniversary walk inside.



Contents

OUR VISION

A world free from Parkinson's.

OUR MISSION

We fund and facilitate research that has the potential to cure Parkinson's. We're working with urgency to find new treatments that can slow, stop or reverse the condition.

ABOUT US

Welcome from Helen Matthews, CEO	3
----------------------------------	---

OUR RESEARCH

An update to our research strategy	4
Combination therapies	5
The 2025 iLCT meeting - a new alliance for progress	6
Update on the iLCT pipeline projects	7
Professor Matthew Farrer awarded 2025 Tom Isaacs Award	8
Stay informed: research, advocacy, and community	9
Largest clinical trial for Parkinson's is now open for recruitment	10-11

OUR FUNDRAISING

Double your impact this Christmas with the Big Give	12
A thank you to Ozzy Osbourne	13
One step closer to a cure	14-15
Our Fundraisers of the Year	16
Incredible fundraisers	17
Join us in making a difference	18
Bring your colleagues together to support Parkinson's research	19
Leave a gift in your Will to Cure Parkinson's	20

Cover photo: Professor Tom Foltynie, co-lead of the EJS ACT-PD trial platform with Katy O'Malley, who lives with Parkinson's.

Welcome from Helen Matthews, CEO

As we move into the final weeks of 2025 and reflect, I'm genuinely optimistic that the progress we've made this year will have a lasting, positive impact - both on how we test treatments for Parkinson's, and on our ability to deliver curative treatments for people living with the condition, in the near future.

We are delighted that the biggest ever disease-modifying trial for Parkinson's in the UK has begun recruitment, with the first two research sites now open. EJS ACT-PD aims to revolutionise clinical trials for Parkinson's and over the coming months will be seeking participants at over 40 sites around the UK.

This autumn we shared our updated research strategy, which aims to set out a clear pathway to support our goal to identify, test and progress disease-modifying therapies for Parkinson's.

One of the pillars of the research strategy is a focus on combination therapies, which we believe could have a greater impact on the progression of Parkinson's. We recently announced a funding call to support trials and preclinical projects in this innovative area of research.

We have long recognised that a cure will only be achieved through collaboration with the whole Parkinson's community. Each year, the Tom Isaacs Award recognises a researcher who works with the community to drive progress in Parkinson's research. Read about the winner on page 8.

This year, we asked you to help us mark our 20th year by taking on walking challenges, concluding with our Walk To Cure Parkinson's in London. We were truly blown away by the response and have been inspired by your stories, pictures and inventive approaches to the challenge.

To all of you who have made this, the charity's 20th year, so significant, for your donations, your fundraising and sharing our vision of a world free from Parkinson's, THANK YOU.



Pictured above: Helen Matthews during our 20th Anniversary Walk To Cure Parkinson's in London.

And it's not over yet. Please consider supporting our Big Give Christmas Challenge. Donations made between 2 and 9 December via the Big Give website will be doubled! See page 12 for details. And check out our Christmas shop for a wonderful selection of Christmas cards.

Finally, we were incredibly sad to hear the news of Ozzy Osbourne's passing. A rock legend who lived with Parkinson's, Ozzy did an enormous amount to raise the profile of the condition and we were honoured to be one of the beneficiary charities of Black Sabbath's "Back to the Beginning" show.

Helen Matthews, CEO Cure Parkinson's

An update to our research strategy

Over the past 20 years, Cure Parkinson's has directly committed more than £20 million of funding into both laboratory and clinical research projects, all focused on slowing, stopping, and reversing Parkinson's progression. Our actions are driven by our core research strategy, which has now been updated.

The strategy has four key objectives that build on what we have done so far and will drive us closer to our goal. Learn more about each of these objectives and the efforts we are making to accelerate the discovery of a cure.



1. Grow our treatment selection programme.

In 2012, Cure Parkinson's and Van Andel Institute joined forces to launch the International Linked Clinical Trials (iLCT) initiative. This involves a committee of 20-30 Parkinson's experts from around the world meeting annually to prioritise promising drugs for trials. Now, Cure Parkinson's seeks to expand this initiative. One way we are doing this is by encouraging cross-condition collaborations. Learn more about our joint iLCT session with Alzheimer's Research UK on page 6.



2. Accelerate the clinical testing of new therapies.

Setting up clinical trials is an expensive, time-consuming process. To accelerate this, Cure Parkinson's has aided the funding and development of several global multi-arm, multi-stage (MAMS) clinical trial platforms - trials that allow the testing of multiple treatments simultaneously. Learn about the upcoming UK MAMS platform, EJS ACT-PD, on pages 10-11.



3. Champion the development of combination therapies.

To date, most experimental treatments are testing a single drug targeting a single aspect of the condition. We know, however, that Parkinson's is a complex condition with many underlying drivers. Therefore, it may be more effective to treat Parkinson's with combinations of drugs that target different aspects of the condition. Learn more about our newest funding call on page 5.



4. Make disease modification more personalised.

As many in the patient community know, the symptoms of Parkinson's can vary widely between people affected by the condition. This can make it hard to determine the effectiveness of the treatment in a trial, as each person may respond to the treatment differently. To increase the likelihood of success, we are interested in improving patient stratification for clinical trials and helping researchers identify who may benefit from the therapy the most.

Our clear focus means we are relentless in our pursuit of these objectives and the ultimate goal of disease modification for Parkinson's. We will bring together those who share this ambition and work collaboratively with them as we all strive for a world without Parkinson's.

You can read the full research strategy on our website at cureparkinsons.org.uk/research-strategy

Combination therapies

As part of our updated research strategy, Cure Parkinson's seeks to encourage the development of combination therapies. To achieve this, we are excited to announce our newest funding call, which will give £2 million to support both preclinical and clinical investigations of combination therapies.

Most clinical trials for disease modification in Parkinson's have involved the testing of a single drug (or monotherapy) in the hope it will have a clinical benefit. Monotherapies are helpful when an individual factor causes a condition, and this factor is well understood. For example, antibiotics are used to treat strep throat because it is caused by bacteria. We know, however, that there are many pathways that interact and contribute to the loss of nerve cells (neurons) in Parkinson's. Therefore, although the clinical testing of single drugs remains important, finding a disease-modifying treatment may ultimately require a combination therapy approach.

A combination therapy is a treatment that involves two or more active agents to achieve the desired effect. These drugs may target separate pathways linked to the condition, or one may be used to enhance the effectiveness of the other.

Combination therapies have already been employed in several therapeutic areas, such as in cancer and heart disease and are currently used to treat Parkinson's symptoms: co-careldopa, one of the most common Parkinson's medications, contains both levodopa and carbidopa. Carbidopa helps to ensure more levodopa can reach the brain, where it is then converted to dopamine.

Since combination therapies are already being used for the treatment of Parkinson's symptoms, it feels logical that they could also be used to treat progression. Therefore, Cure Parkinson's is championing the testing of combination therapies with the hope of increasing the odds of identifying disease-modifying therapies quickly.



// Parkinson's is a complex condition, as our understanding increases it becomes increasingly clear that multiple cellular mechanisms should be targeted to have the best chance of restoring cellular health. This means exploring and testing combination therapies is a critical next step in drug discovery and highlights an important step to getting new therapies to the clinic.

Professor Heather Mortiboys
University of Sheffield

To drive this, Cure Parkinson's opened a new £2 million funding call in October, asking researchers to submit proposals for both preclinical and clinical projects testing combination therapies for Parkinson's. The call will close for applications on Monday 24 November 2025.

Learn more about this call and how to apply on our website at cureparkinsons.org.uk/combo-funding-announcement

The 2025 iLCT meeting - a new alliance for progress

This year marks a new milestone for the International Linked Clinical Trials (iLCT) programme. At the annual meeting in June, the committee were joined by members of Alzheimer's Research UK (ARUK) and dementia experts for a special joint session looking at drugs that may benefit both Parkinson's and dementia.

Since 2012, Cure Parkinson's and the Van Andel Institute (VAI) have assembled a group of world-leading Parkinson's experts to evaluate treatments with the potential to slow, stop or reverse Parkinson's, with the aim to accelerate their advancement into clinical trials.

This year's meeting took place in June at Cumberland Lodge in Windsor Great Park. The Cure Parkinson's research team provided 16 drug dossiers for review. The iLCT committee evaluated each dossier, with every member providing a score which contributed to the overall ranking and prioritisation of the treatments. This ranking is based on how ready each drug is to move into clinical trial. Following careful consideration, the committee prioritised five drugs to be taken forward to the next stages of testing, with each drug addressing different aspects of Parkinson's biology.

We were also delighted to announce a new partnership with ARUK, the leading dementia research charity in the UK. There are many similarities in the drivers and underlying biology of neurodegenerative conditions, including Parkinson's, Alzheimer's and other

dementias. For example, a common feature is the accumulation of dysfunctional proteins in neurons; in Parkinson's, this is alpha-synuclein, whereas in Alzheimer's, this is amyloid beta and tau. Recognising the overlap, this collaboration seeks to assess the potential for certain treatments to offer therapeutic benefits for Parkinson's, Alzheimer's, and related dementias. Learn more about this partnership on our website at cureparkinsons.org.uk/aruk-partnership

During the iLCT meeting, Cure Parkinson's and ARUK hosted a special joint session. Several dementia experts joined a panel with a selection of iLCT committee members to evaluate six drugs targeting common biological pathways. As a result, the organisations are now in discussion on how best to move forward with these drugs as well as future directions for the collaboration.

As part of our updated research strategy, Cure Parkinson's will continue to look at new ways to grow and strengthen our iLCT initiative to further accelerate the identification and progression of promising treatments.



Update on the iLCT pipeline projects

Another of our grant funding calls - the International Linked Clinical Trials (iLCT) Pipeline Acceleration Programme - uses guidance from the iLCT committee to commission research into promising drugs that need additional preclinical research before being ready to move into clinical trial.

Since its launch in 2022, we have funded four projects under this grant programme. Read the latest updates on two of these projects below, including our newest addition.

Theracurmin

Curcumin, a compound found in turmeric, is known for its antioxidant and anti-inflammatory properties; because of this, researchers have been interested in whether it may be able to help rescue neurons in Parkinson's. Curcumin, however, has low bioavailability, meaning it does not circulate throughout the body well. Theracurmin is a slow-release formulation of curcumin that is much that is much more bioavailable. To assess whether this formulation can access the brain and if it is neuroprotective, Dr Ayse Ulusoy at the German Center for Neurodegenerative Diseases (DZNE) will be investigating Theracurmin in preclinical models of Parkinson's. This 18-month project will start in November 2025, and we look forward to seeing how it progresses.

Probucol and Chlorogenic Acid

Dr Poonam Thakur, from the Indian Institute of Science Education and Research (IISER) in Thiruvananthapuram, is evaluating two drugs – probucol and chlorogenic acid – in models of Parkinson's to determine whether they are neuroprotective. Probucol is a cholesterol medication and evidence suggests that it can lower inflammation. Chlorogenic acid is a compound found in coffee which is thought to reduce levels of the protein alpha-synuclein.

So far, the team have been able to confirm that both compounds were able to reach the brain; however, initial analyses have not shown a strong effect from either. The researchers will continue to examine the data from additional treatment groups over the next year, with the project expected to finish in September 2026.



“If the outcome in our preclinical evaluation is successful, then I'll be very happy if any of these drugs go to a clinical trial. For me to contribute to any benefit for people with Parkinson's, will give me immense satisfaction.”

**Dr Poonam Thakur
Indian Institute of Science Education and Research**

Learn more about Dr Thakur and her work in Cure Parkinson's new Meet the Researcher series, as we hear directly from the scientists putting our funded research projects into action. From learning about their career journeys, to getting an inside look at their studies, we discover how their work aims to support people living with Parkinson's. Read more on our website at cureparkinsons.org.uk/dr-poonam-thakur or read more about the projects we fund on our website at cureparkinsons.org.uk/research-projects

Professor Matthew Farrer awarded 2025 Tom Isaacs Award

Cure Parkinson's and Van Andel Institute are delighted to announce Dr Matthew Farrer as the winner of the 2025 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson's community.

Cure Parkinson's CEO Helen Matthews presented the award to Dr Farrer at the annual Grand Challenges in Parkinson's Disease symposium and parallel Rallying to the Challenge meeting for people living with Parkinson's. These events are held simultaneously in Grand Rapids, Michigan.

Dr Farrer is a Professor of Neurology at the University of Florida, where he specialises in Molecular Neuroscience and Neurogenetics. Dr Farrer's work in the genetics and neuroscience of Parkinson's is critically acclaimed, and focuses on uniting people with Parkinson's and researchers for their mutual benefit.

“We are delighted to present the 2025 Tom Isaacs Award to Matt. Through his work he truly understands the importance and value of working with people with Parkinson's and how insights from the lived experience of Parkinson's can drive research. We hope this award will help celebrate Matt's passion and commitment to the Parkinson's community.”

Helen Matthews



“I feel very humbled to receive the Tom Isaacs Award. None of this would be possible without people with Parkinson's and their families, who are at the heart of every discovery. From identifying genes like alpha-synuclein, LRRK2, PINK1 and PARKIN to uncovering the roles of mitochondria and lysosomes, the biggest breakthroughs have come from studying families affected by Parkinson's. Their genealogy and personal medical perspective have given us cause-and-effect insights that guide the future of research, and we need more focus and funding in this area to truly make a difference. Their knowledge of Parkinson's is second to none, and it's humbling to learn from them.”

Dr Matthew Farrer

Stay informed: research, advocacy, and community

Catch up on some of our key events from the year where we share the latest developments in Parkinson's research and updates on our research funding and find out how you can join our advocacy community helping to support our mission.


Research Update Meeting

Rewatch our Autumn Research Update Meeting focused on multi-arm, multi-stage (MAMS) clinical trial platforms, with presentations from two upcoming MAMS projects: EJS ACT-PD, a UK-based MAMS platform, and SLEIPNIR, a multi-arm clinical trial platform recently launched in Norway - cureparkinsons.org.uk/autumn-rum-25



Get involved with the Cure Parkinson's Advocacy Community

At Cure Parkinson's, the volunteers who are part of our advocacy community play a crucial role in helping support our mission – from shaping research priorities, to sharing their experiences to help raise awareness about living with Parkinson's. Find out more and how to get involved on our website at cureparkinsons.org.uk/advocacy-get-involved



Rallying to the Challenge

Re-watch presentations from this year's Rallying to the Challenge meeting discussing Waste Disposal Systems in Parkinson's. The meeting, designed for, and by, people with Parkinson's, advocates, and care partners, explores how the Parkinson's community can impact and accelerate research - cureparkinsons.org.uk/rallying-2025

Quarterly webinar series

Our most recent quarterly webinar, hosted by Professor Tilo Kunath at the University of Edinburgh in collaboration with the Journal of Parkinson's Disease, explored Deep Brain Simulation (DBS), with a special emphasis on an emerging form of this therapy: adaptive DBS. The panel discussed how the therapy works and interacts with the brain, and whether DBS, especially adaptive DBS, could have a disease-modifying effect. Re-watch the webinar on our website at cureparkinsons.org.uk/webinars

The largest clinical trial for Parkinson's is now open for recruitment

Cure Parkinson's is excited to announce that the first multi-arm multi-stage clinical trial platform for Parkinson's in the UK - EJS ACT-PD - is underway, with recruitment now open to people with Parkinson's.

The Edmond J. Safra Accelerating Clinical Trials for Parkinson's Disease (EJS ACT-PD) platform aims to transform the way Parkinson's clinical trials are conducted in the UK. As a multi-arm, multi-stage (MAMS) trial platform, EJS ACT-PD can evaluate several potentially disease-modifying treatments in parallel against a shared placebo (dummy drug) group, accelerating the search for effective treatments by testing more drugs faster and more efficiently than ever before.

Co-led by Professors Tom Foltynie (University College London) and Camille Carroll (Newcastle University), the trial will initially test two potentially disease-modifying therapies - telmisartan and terazosin. In 2026, the team will introduce a third treatment arm with ursodeoxycholic acid (UDCA). All three drugs are repurposed from other medical conditions and were previously evaluated by our International Linked Clinical Trials (iLCT) committee - a group of Parkinson's experts who meet annually to rank and prioritise promising therapies for clinical trial.

Why is this important for people living with Parkinson's?

Operating a clinical trial is a slow, and expensive process, which must be restarted each time researchers want to test a new drug. It is comparable to building a football stadium, playing a single game, and then dismantling the stadium, only to restart the process for each subsequent trial. Multi-arm multi-stage (MAMS) trials can speed up this process by testing multiple treatment groups against one placebo. This allows for several drugs to be tested in parallel. MAMS platforms are also adaptive, allowing new treatments to be added as others

complete or swapped in if drugs are not showing positive results. This flexibility effectively speeds up the trial process.

The MAMS model has already been successfully applied in other conditions, such as prostate cancer, and Multiple Sclerosis. Additionally, the launch of this trial means more opportunity than ever before for people with Parkinson's to participate in clinical research - in the first instance, EJS ACT-PD will recruit up to 1,600 participants across more than 40 sites in England, Wales, Northern Ireland, and Scotland.

This trial is a £26 million investment and the result of several years' work by the EJS ACT-PD consortium. The consortium invited stakeholders from a variety of backgrounds, including researchers, clinicians, charities, and people with Parkinson's, to help design and launch this trial. Cure Parkinson's has played an essential role in supporting this initiative since its inception, and we are delighted to see it come to fruition.

Involvement and impact of people with Parkinson's

Since the beginning, a central goal for this project has been to make it accessible and inclusive. This has meant involving diverse groups to help shape the trial design, ensuring it produces results that are meaningful to people with Parkinson's. To achieve this, the consortium recruited people with Parkinson's, their partners and carers, as well as community representatives to the Patient and Public Involvement and Engagement (PPIE) working group. Members sat on each of the other working groups, helping to ensure that people with Parkinson's were considered in every step of the process.



“ The patient voice is valuable in clinical trials, it’s the voice of reality yet it’s often overlooked, so it’s really positive that the trial platform genuinely values it. I wanted to use my own skills and experiences to do something really impactful and help ensure the trials platform takes the patient perspective into account.

Katy O’Malley, who lives with Parkinson’s and is a member of the PPIE working group

Learn more about MAMS platforms in our recent webinar at cureparkinsons.org.uk/trial-designs-webinar

Learn more about the trial and how you can register your interest at ejsactpd.com/

“ CP understood the transformative potential of EJS ACT-PD and has supported the study team since 2018/2019 to make this a reality. We are very proud to have worked hard behind the scenes to facilitate around a third of the funding required for the trial, for which we thank our incredible supporters - and that is you. It is fantastic that the trial is including three drugs already prioritised by our iLCT Committee which means that treatments we believe are among those with the most potential to be disease-modifying are moving forward in clinical testing.

Helen Matthews, Cure Parkinson’s CEO

This clinical trial is led by University College London and is funded by a Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) partnership, Cure Parkinson’s, The Michael J Fox Foundation, Parkinson’s UK, The John Black Charitable Foundation, The Gatsby Charitable Foundation and Van Andel Institute.

A graphic background featuring a repeating pattern of stylized human head profiles in blue and orange. In the center, there is a large, solid blue circle with a white outline. Inside this circle, the text "EJS ACT-PD" is written in a white, sans-serif font.

Double your impact this Christmas with the Big Give

We're delighted to be taking part once again in the Big Give Christmas Challenge, the UK's biggest match-funding campaign, and we'd love for you to join us between 2 and 9 December, where any donation you make to Cure Parkinson's will be doubled.

Last year, your support helped us raise over £86,000 for research, and we'd love for you to help us again this year. The Big Give brings together charities, generous pledgers, and public donations to create something extraordinary.

Every donation you make to Cure Parkinson's during the campaign week will be doubled at no extra cost to you. That means a gift of £50 instantly becomes £100, and £250 turns into £500 - all going directly towards funding groundbreaking research.

This year, the funds raised will support the EJS ACT-PD Trial, one of our most ambitious initiatives yet: a pioneering trial platform designed to accelerate progress towards treatments that could slow, stop, or even reverse Parkinson's. You can read more about the project on pages 10-11, but what matters most is that your support will be at the heart of making it possible.

HOW IT WORKS

When to give. The campaign runs from Tuesday 2 December until Tuesday 9 December at 12 noon.

Where to give. All donations must be made through our dedicated Big Give webpage. You can learn more and be directed there via our website: cureparkinsons.org.uk/big-give-2025

What happens next. Every donation made during this week will be matched pound-for-pound, doubling the impact of your generosity.

By taking part in the Big Give, you'll not only be supporting our vital research but also join a community determined to bring hope to those living with Parkinson's.

So, please save the dates in your diary, and consider making a donation that will go twice as far in the race to find a cure.

All of our Big Give pledgers this year are part of our Cure Collective, a philanthropic giving circle. If you'd like to find out more about the Cure Collective, please visit our website at cureparkinsons.org.uk/cure-collective



“I've been involved with Cure Parkinson's since 2014, after my mother was diagnosed with the condition. Over the years, I've been proud to support the charity in any way I can, and in 2024 I was delighted to become co-chair of the Cure Collective.

Together with some of my fellow Cure Collective members, we've pledged funds to be matched by the public as part of The Big Give. Having supported this campaign in previous years, I know just how powerful it can be for Cure Parkinson's and how much of a difference it can make. I'm truly proud to be part of that.

Andrew Moncrieff, co-chair of the Cure Collective

A thank you to Ozzy Osbourne

Ozzy Osbourne puts the spotlight on Parkinson's with his final performance.

We were delighted to have been chosen as one of the three beneficiary charities of Black Sabbath's iconic Back to the Beginning concert, alongside Birmingham Children's Hospital and Acorns Children's Hospice.

The funds donated to us will go towards our vital Parkinson's research, including trials we are funding that will involve people with Parkinson's in Birmingham and the West Midlands.

The concert saw the original members of Black Sabbath – Ozzy, Geezer Butler, Tony Iommi, and Bill Ward – reunite for the first time in 20 years to play in their hometown of Birmingham. Held at Villa Park on 5 July, the show featured an incredible all-star lineup of other heavy metal bands and performers including Metallica, Slayer and Guns N' Roses.

Over 40,000 people attended, with 5.8 million estimated to be watching via the official livestream. For Ozzy, the show marked his final performance on stage before he sadly died on 22 July.

After publicly revealing his Parkinson's diagnosis in 2020 Ozzy often spoke candidly about his experience of living with the condition, from the highs to the lows, raising the profile of Parkinson's around the world. His determination to perform once again – in his hometown with his original Black Sabbath bandmates – was inspirational, and the funds raised from Back to the Beginning will leave a legacy on our vital research.

We are very grateful to Ozzy, Sharon and Black Sabbath for choosing to support Cure Parkinson's with the Back to the Beginning concert, and our thoughts were with the whole Osbourne family when we heard the sad news of Ozzy's death.




One step closer to a cure

Inspired by our late co-founder Tom Isaacs' 4,500 mile walk around the British coast, we asked supporters old and new to Walk To Cure Parkinson's to mark the charity's 20th year.

In 2002 Tom set off on Coastin': a year-long walk around the coastline of Britain to raise funds for research into a cure. He went on to co-found Cure Parkinson's in 2005, alongside three other people living with the condition.

In the 20 years since then we have funded millions of pounds of research, made scientific discoveries and opened new avenues of research. However, we don't yet have a cure and so our goal remains unchanged: to consign Parkinson's to medical history.

To pay homage to Tom and raise even more funds in support of our vital research, this year we have been encouraging our supporters to Walk To Cure Parkinson's, either by organising their own walk or taking part in our 10km or 20km walk in London.



We have been amazed by the walks you have taken on for us over the year. From walking around the Isle of Wight, completing Wainwright's coast to coast path, to taking on stretches of the Saxon Shore Way. We are so grateful for all the fundraising efforts and inspired by the incredible awareness you've helped raise for the charity.

Plus, over 140 of you joined us in London on Sunday 28 September for our in-person Walk To Cure Parkinson's event. Many took on the 20km challenge, setting off from Greenwich Park, before meeting up with the 10km walkers at Bermondsey. The routes snaked along the Thames towards the finish line on Millennium Bridge - where Tom started and completed his Coastin' walk - and it was lovely to see so many of you for a post-walk celebration at the Samuel Pepys pub.

Thank you for everyone who got involved with Walk To Cure Parkinson's this year - together you've helped to raise over £39,500!



Our Fundraisers of the Year

Each year we celebrate fundraisers who have gone above and beyond in support of our vital Parkinson's research with our Fundraiser of the Year award. This year's winners - mother-daughter duo Rebecca and Lily Whitehurst - certainly went the extra mile.

The Whitehurst family have fundraised for Cure Parkinson's over the years as the cause is very close to their hearts; Rebecca's dad (Lily's grandad) lived with Parkinson's for 20 years, and her husband (Lily's dad) was diagnosed with the condition in 2010.

In 2024, Rebecca and Lily decided to take on one of their most challenging fundraisers to date by walking the Pembrokeshire coast path. They covered 186 miles in 16 days and raised a phenomenal £8,000.

In the year leading up to the 186 mile walk they went on hikes whenever they could, gradually increasing the distance and difficulty. When they set off for the fundraiser in August 2024, the pair walked between 10 and 15 miles each day and certainly encountered more than their fair share of challenges, including bad blisters, torrential rain and gale force winds.

To document their adventure, they set up an Instagram account dedicated to their fundraiser (@coastpath4parkinsons), helping to raise the profile of their challenge and update their supporters.

To keep them motivated during the 16 day adventure they relied on their incredible family and friends for support, plus the stunning Pembrokeshire coastline to lift their spirits.

“We had different people join us on our walks almost every day, as well as a network of supporters that drove us to and from start and end locations, and even cooked the occasional meal for us. Without a doubt we could not have done it without them. And when the sun shone and the Pembrokeshire coast was there in all its glory, it all seemed much more possible.”

Rebecca Whitehurst

We are extremely grateful to Rebecca and Lily for their incredible support and wish them a huge congratulations for being our Fundraisers of the Year!



Incredible fundraisers

This year marks 20 years of Cure Parkinson's, and thanks to our fabulous fundraisers, it's been one of our best yet! From sporting challenges to wonderful community events, we have been blown away by your support. Read on for some highlights.

2025 has been an incredible year for our fundraisers, from baking to golf and even a 5km inflatable obstacle course.

Committed supporter Tommy Hartshorn has now held five golf days in aid of Cure Parkinson's. From enjoyable golf to brilliant dinners, Tommy's events have always been a huge success.



“Each year, I organise a golf day to raise as much money as possible for this amazing charity. Their drive to find a cure is truly remarkable, and I do as much as I can to support their efforts, to help make the lives of my loved ones better for the future.

Tommy Hartshorn

Caleb and Brodie Nicholson alongside their parents Craig and Jennifer, completed the Glasgow Inflatable 5km race in support of their grandad Andy and great uncle John raising over £1,800.

Cathie started fundraising for Cure Parkinson's in March 2025 to honour her brother who lived with Parkinson's. Since then, Cathie has raised an incredible £3,750 from selling cakes, jams and chutneys, as well as some collectible items. Thank you, Cathie!



Pictured above: The Nicolson family ready to take on the Inflatable 5k race and Cathie's jam and chutney sale.

Sandra Pratt and friends organised a Time for Tea event, raising over £3,000. As well as enjoying a delicious selection of treats, guests were able to buy books, take part in a raffle and tombola and even enjoy a hand massage all whilst raising vital funds for Cure Parkinson's.

In May 2022, 82-year-old David Temple took on a four-week mission to sail around the coast of Britain to fundraise for Parkinson's research. Inspired by his wife Hazel, who lives with Parkinson's, David has now released 'Voyage for a Cure', which recounts a remarkable tale of adventure, perseverance and pure determination.

All proceeds from the book go towards Cure Parkinson's which can be purchased at voyageforacure.bigcartel.com

Have any of these incredible fundraisers inspired you to organise your own community event? If so, get in touch with a friendly member of our events team who can support you all the way by emailing events@cureparkinsons.org.uk

Join us in making a difference

Whether through attending an upcoming event, planning your own fundraising or taking on a challenge event in the New Year, your support helps bring us one step closer to a cure.

With the festive season just around the corner, many of our supporters are starting to get plans together for festive fundraisers.

Last year fundraiser Joya Logan and Celestial Music arranged 'A Celestial Christmas' in Battersea raising an incredible £10,000 for Parkinson's research. The evening featured much loved Christmas classics and pieces specially composed for the event.



We are delighted that this special event will return on 16 December at St Luke's Church in Battersea. To reserve your place, please visit our website at cureparkinsons.org.uk/celestial-christmas

Or if you're feeling inspired to spread some festive cheer by organising your own fundraising event - with friends and family or with your school, church, or community group - we'd love to hear from you. Every effort makes a real difference to our work. Please get in touch with our fundraising team by emailing events@cureparkinsons.org.uk

Start the New Year by joining Team Cure at one of our many challenge events taking place across the UK. Here's a few highlights of what we have on offer.



TCS London Marathon 2026 26 April 2026

If you're lucky enough to secure a place when the ballot results are released and want to raise crucial funds for Cure Parkinson's we love to hear from you.

Hackney Half Marathon 17 May 2026

Hackney is an exciting borough with vibrant street art and the 13 mile route of the Hackney Half is designed to showcase its culture! Full of twists and turns, local landmarks and the Olympic Park.

London to Brighton Cycle 21 June 2026

Starting at Clapham Common, the 54 mile cycle will take you through the capital to the beautiful countryside of the South Downs all the way to Brighton's seafront. All ages and experiences are welcome, so whether you're a cycling fanatic or thinking of signing up for your first race, this is the event for you! To see all our challenge events and sign up please visit our website at cureparkinsons.org.uk/events

Bring your colleagues together to support Parkinson's research

From rewarding team-building activities to meaningful challenges, no matter the size of your organisation there are lots of creative ways you can team up with colleagues to help find a cure. Here are some of our favourite ideas.



Winter bake-off

Bring in your favourite seasonal bakes to share. Sell the treats for donations and award prizes for the best presentation and tastiest bakes.

Dress down office day

Swap office wear for PJs, hoodies, or onesies. Donate to dress down and keep things cosy.

Winter warmer drinks station

Set up a drinks station with specialty teas, coffee, hot chocolate, syrups, and toppings. Ask for a small donation per drink.

Office quiz

Stay warm indoors and test your trivia skills! Host a general knowledge or themed quiz with teams paying to enter.

New Year reset

Whether you're going guilty pleasure free, tracking your steps, or cycling miles, raise sponsorship and push each other to new goals. It's a great way to boost team spirit, stay active, and raise vital funds for Cure Parkinson's.

Got the fitness bug?

We're excited to offer charity places in the Hackney Half Marathon 2026 and we'd love for your company to join Team Cure!

// A group of Sarasin employees are taking on the Hackney Half Marathon next year! We are very excited to be running as a team, having fun outside the office together and raising money for such a good cause.

Rachel Barnes, Sarasin & Partners



Or if you fancy taking on an obstacle course, why not try Tough Mudder? Run, climb and crawl for #TeamCure and prove to your fellow colleagues just how tough you really are! Places are available at various locations throughout the year.

For more fundraising ideas and information on challenges, please visit our website at cureparkinsons.org.uk/corporate-partnerships. Do you have a unique idea? Get in touch with Lili at corporate@cureparkinsons.org.uk

Leave a gift in your Will to Cure Parkinson's

Imagine a future free from Parkinson's. At Cure Parkinson's, we are working towards that day by funding pioneering research that brings hope now and for the future.

Legacy gifts make this possible. They provide us with the regular support that we need to plan ambitious projects that could one day deliver the cure, whilst leaving a meaningful legacy that lasts beyond your lifetime.

Find out more - request our free new Gifts in Wills Guide today by:

Visiting our website
cureparkinsons.org.uk/leave-a-gift-in-your-will

Or email Rosa, our Individual Giving and Legacies Manager, at
rosa@cureparkinsons.org.uk



cureparkinsons.org.uk

amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES

FR
Registered with
FUNDRAISING
REGULATOR

Cure Parkinson's is the operating name of The Cure Parkinson's Trust. The Cure Parkinson's Trust is a registered charity in England and Wales (1111816) and Scotland (SCO44368) and a company limited by guarantee - company number 05539974 (England and Wales).